Financial News
Latest News about NVO
Recent news which mentions NVO
   Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
   
  September 24, 2024
  Tickers 
   NVO
  
  
  From Benzinga
 
   Novo Nordisk's Options: A Look at What the Big Money is Thinking
   
  September 24, 2024
  Tickers 
   NVO
  
  
  From Benzinga
 
   'Miracle' Weight Loss Drug Ozempic To Enter US Price Negotiations Within A Year, Novo Nordisk CEO Says Ahead Of Senate Hearing
   
  
  
  September 24, 2024
  From Benzinga
 
   2 Weight-Loss Stocks That Could Rocket Higher This Year
   
  
  
  September 24, 2024
  From Motley Fool
 
   Nasdaq-Traded Cannabinoid Biotech Corbus Pharma Stock Plunges 60%, But Analysts Say 'Buy The Dip' Now
   
  
  
  September 23, 2024
  From Benzinga
 
   Novo Nordisk CEO To Face Senate Scrutiny Over High Ozempic And Wegovy Prices, Hearing Scheduled On Tuesday
   
  
  
  September 23, 2024
  From Benzinga
 
   Novo Nordisk's Options: A Look at What the Big Money is Thinking
   
  September 23, 2024
  Tickers 
   NVO
  
  
  From Benzinga
 
   Bernie Sanders Questions Why Your Monthly Ozempic Prescription Costs More Than A Luxury Handbag When It Can Be Sold For Less Than $100
   
  
  
  September 22, 2024
  From Benzinga
 
   Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
   
  
  
  September 22, 2024
  From Benzinga
 
   Why Novo Nordisk Stock Fell While Eli Lilly and Viking Therapeutics Bumped Higher Today
   
  
  
  September 20, 2024
  From Motley Fool
 
   US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices
   
  
  
  September 20, 2024
  From Benzinga
 
   Novo Nordisk's Monlunabant Data Drags Stocks Of Smaller Players
   
  
  
  September 20, 2024
  From Benzinga
 
   Corbus Pharma (CRBP) Stock Drops 60% After Novo Nordisk's Cannabinoid-Based Weight Loss Drug Trial Disappoints
   
  
  
  September 20, 2024
  From Benzinga
 
   Novo Nordisk Stock Declines After Headline Results From Mid-Stage Study Of Monlunabant In Obese Patients
   
  
  
  September 20, 2024
  From Benzinga
 
   European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
   
  
  
  September 20, 2024
  From Benzinga
 
   Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
   
  
  
  September 19, 2024
  From Benzinga
 
   Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
   
  September 19, 2024
  Tickers 
   NVO
  
  
  From Benzinga
 
   Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
   
  
  
  September 19, 2024
  From Motley Fool
 
   Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
   
  
  
  September 19, 2024
  From Motley Fool
 
   Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
   
  
  
  September 18, 2024
  From Benzinga
 
   1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
   
  
  
  September 17, 2024
  From Motley Fool
 
   2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
   
  
  
  September 14, 2024
  From Motley Fool
 
   3 No-Brainer Biotech Stocks to Buy With $200 Right Now
   
  
  
  September 12, 2024
  From Motley Fool
 
   Why Roche Holdings Stock Withered on Wednesday
   
  
  
  September 11, 2024
  From Motley Fool
 
   Why Viking Therapeutics Stock Rocked the Market Today
   
  
  
  September 11, 2024
  From Motley Fool
 From Benzinga
 
   Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
   
  
  
  September 11, 2024
  From Benzinga
 
   Is Hims & Hers Health the Next Teladoc?
   
  
  
  September 11, 2024
  From Motley Fool
 
   Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
   
  
  
  September 11, 2024
  From Benzinga
 
   Evaluating Novo Nordisk: Insights From 8 Financial Analysts
   
  September 09, 2024
  Tickers 
   NVO
  
  
  From Benzinga
 
   Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  
  
 Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
  © 2025 FinancialContent. All rights reserved.
 

 
  
 
 
 










